Forecasted COVID-19 vaccine share of total mRNA revenues globally 2021-2035

Published by
Matej Mikulic,
Sep 17, 2021
In 2028, around 86 percent of all forecasted revenue of mRNA products is expected to be from COVID-19 vaccines. This statistic illustrates the share of COVID-19 vaccine revenue of total forecasted revenues from mRNA products worldwide from 2021 to 2035.

Share of COVID-19 vaccine revenue of total forecasted mRNA product revenue worldwide from 2021 to 2035

Loading statistic...

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

September 2021

Region

Worldwide

Survey time period

as of September 2021

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " mRNA technology "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you mRNA technology

Overview

5

Research and development

5

COVID-19

6

Leading companies

4

Focus: Moderna

5

Focus: BioNTech

4

Further related statistics

11

Further Content: You might find this interesting as well

Statistics

Topics

ModernaGlobal pharmaceutical industryPfizerBioNTechVaccinations in the U.S.
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.
Menu